BACKGROUND: Individuals with cryptococcal antigenemia are at high risk of developing cryptococcal meningitis if untreated. The progression and timing from asymptomatic infection to cryptococcal meningitis is unclear. We describe a subpopulation of individuals with neurologic symptomatic cryptococcal antigenemia but negative cerebral spinal fluid (CSF) studies. METHODS: We evaluated 1201 human immunodeficiency virus-seropositive individuals hospitalized with suspected meningitis in Kampala and Mbarara, Uganda. Baseline characteristics and clinical outcomes of participants with neurologic-symptomatic cryptococcal antigenemia and negative CSF cryptococcal antigen (CrAg) were compared to participants with confirmed CSF CrAg+ cryptococcal meningitis. Additional CSF testing included microscopy, fungal culture, bacterial culture, tuberculosis culture, multiplex FilmArray polymerase chain reaction (PCR; Biofire), and Xpert MTB/Rif. RESULTS: We found 56% (671/1201) of participants had confirmed CSF CrAg+ cryptococcal meningitis and 4% (54/1201) had neurologic symptomatic cryptococcal antigenemia with negative CSF CrAg. Of those with negative CSF CrAg, 9% (5/54) had Cryptococcus isolated on CSF culture (n = 3) or PCR (n = 2) and 11% (6/54) had confirmed tuberculous meningitis. CSF CrAg-negative patients had lower proportions with CSF pleocytosis (16% vs 26% with ≥5 white cells/μL) and CSF opening pressure >200 mmH2O (16% vs 71%) compared with CSF CrAg-positive patients. No cases of bacterial or viral meningitis were detected by CSF PCR or culture. In-hospital mortality was similar between symptomatic cryptococcal antigenemia (32%) and cryptococcal meningitis (31%; P = .91). CONCLUSIONS: Cryptococcal antigenemia with meningitis symptoms was the third most common meningitis etiology. We postulate this is early cryptococcal meningoencephalitis. Fluconazole monotherapy was suboptimal despite Cryptococcus-negative CSF. Further studies are warranted to understand the clinical course and optimal management of this distinct entity. CLINICAL TRIALS REGISTRATION: NCT01802385.
BACKGROUND: Individuals with cryptococcal antigenemia are at high risk of developing cryptococcal meningitis if untreated. The progression and timing from asymptomatic infection to cryptococcal meningitis is unclear. We describe a subpopulation of individuals with neurologic symptomatic cryptococcal antigenemia but negative cerebral spinal fluid (CSF) studies. METHODS: We evaluated 1201 human immunodeficiency virus-seropositive individuals hospitalized with suspected meningitis in Kampala and Mbarara, Uganda. Baseline characteristics and clinical outcomes of participants with neurologic-symptomatic cryptococcal antigenemia and negative CSF cryptococcal antigen (CrAg) were compared to participants with confirmed CSF CrAg+ cryptococcal meningitis. Additional CSF testing included microscopy, fungal culture, bacterial culture, tuberculosis culture, multiplex FilmArray polymerase chain reaction (PCR; Biofire), and Xpert MTB/Rif. RESULTS: We found 56% (671/1201) of participants had confirmed CSF CrAg+ cryptococcal meningitis and 4% (54/1201) had neurologic symptomatic cryptococcal antigenemia with negative CSF CrAg. Of those with negative CSF CrAg, 9% (5/54) had Cryptococcus isolated on CSF culture (n = 3) or PCR (n = 2) and 11% (6/54) had confirmed tuberculous meningitis. CSF CrAg-negative patients had lower proportions with CSF pleocytosis (16% vs 26% with ≥5 white cells/μL) and CSF opening pressure >200 mmH2O (16% vs 71%) compared with CSF CrAg-positive patients. No cases of bacterial or viral meningitis were detected by CSF PCR or culture. In-hospital mortality was similar between symptomatic cryptococcal antigenemia (32%) and cryptococcal meningitis (31%; P = .91). CONCLUSIONS:Cryptococcal antigenemia with meningitis symptoms was the third most common meningitis etiology. We postulate this is early cryptococcal meningoencephalitis. Fluconazole monotherapy was suboptimal despite Cryptococcus-negative CSF. Further studies are warranted to understand the clinical course and optimal management of this distinct entity. CLINICAL TRIALS REGISTRATION: NCT01802385.
Authors: David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware Journal: Clin Infect Dis Date: 2010-08-15 Impact factor: 9.079
Authors: Neil French; Katherine Gray; Christine Watera; Jessica Nakiyingi; Eric Lugada; Michael Moore; David Lalloo; James A G Whitworth; Charles F Gilks Journal: AIDS Date: 2002-05-03 Impact factor: 4.177
Authors: Henry Masur; John T Brooks; Constance A Benson; King K Holmes; Alice K Pau; Jonathan E Kaplan Journal: Clin Infect Dis Date: 2014-02-27 Impact factor: 9.079
Authors: John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell Journal: Clin Infect Dis Date: 2010-02-01 Impact factor: 9.079
Authors: N C Bahr; L Tugume; R Rajasingham; R Kiggundu; D A Williams; B Morawski; D Alland; D B Meya; J Rhein; D R Boulware Journal: Int J Tuberc Lung Dis Date: 2015-10 Impact factor: 2.373
Authors: Kara N Durski; Karen M Kuntz; Kosuke Yasukawa; Beth A Virnig; David B Meya; David R Boulware Journal: J Acquir Immune Defic Syndr Date: 2013-07-01 Impact factor: 3.731
Authors: Joseph N Jarvis; Graeme Meintjes; Anthony Williams; Yolande Brown; Tom Crede; Thomas S Harrison Journal: BMC Infect Dis Date: 2010-03-15 Impact factor: 3.090
Authors: Darlisha A Williams; Tadeo Kiiza; Richard Kwizera; Reuben Kiggundu; Sruti Velamakanni; David B Meya; Joshua Rhein; David R Boulware Journal: Clin Infect Dis Date: 2015-04-01 Impact factor: 9.079
Authors: Richard Kwizera; Denis Omali; Kiiza Tadeo; John Kasibante; Morris K Rutakingirwa; Enock Kagimu; Kenneth Ssebambulidde; Darlisha A Williams; Joshua Rhein; David Boulware; David B Meya Journal: J Clin Microbiol Date: 2021-02-18 Impact factor: 5.948
Authors: Prashanth S Ramachandran; Fiona V Cresswell; David B Meya; Charles Langelier; Emily D Crawford; Joseph L DeRisi; David R Boulware; Michael R Wilson Journal: Clin Infect Dis Date: 2019-05-17 Impact factor: 9.079
Authors: David R Boulware; Elizabeth Nalintya; Radha Rajasingham; Paul Kirumira; Rose Naluyima; Fred Turya; Sylvia Namanda; Morris K Rutakingirwa; Caleb P Skipper; Yofesi Nikweri; Kathy Huppler Hullsiek; Ananta S Bangdiwala; David B Meya Journal: Med Mycol Date: 2020-11-10 Impact factor: 4.076
Authors: João Guilherme Pontes Lima Assy; Renato do Carmo Said; Olivia Campos Pinheiro; Alisson Dos Santos Brandão; David R Boulware; Francisco Oscar de Siqueira França; José Ernesto Vidal Journal: Med Mycol Date: 2021-09-03 Impact factor: 4.076
Authors: Jayne Ellis; Ananta S Bangdiwala; Fiona V Cresswell; Joshua Rhein; Edwin Nuwagira; Kenneth Ssebambulidde; Lillian Tugume; Radha Rajasingham; Sarah C Bridge; Conrad Muzoora; David B Meya; David R Boulware Journal: Open Forum Infect Dis Date: 2019-09-29 Impact factor: 3.835